Skip to main content

Table 6 Summary results of the cost-effectiveness analysis

From: Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina

  VKA Suitable Patients
Net Cost USD 135,06
Net Life Years 0,164
Net QALYs 0,172
Cost per Life Year gained USD 823,29
Cost per QALY gained USD 786,08
Cost per Stroke Avoided (Ischemic and Hemorrhagic) USD 5.422,01
Cost per Bleed Avoided (ICH including HS and Major Bleed) USD 3.268,66